Covance Inc. has completed the expansion of its central lab facility in Singapore, enhancing service offerings to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest investment in Singapore, along with recent growth in operations in China and Japan.
 
The 29,000-sq.-ft. lab provides clinical testing services to clients in Asia, including South Korea, Taiwan, Hong Kong, the Philippines, Australia, and India. This expansion doubles the size of Covance’s genomics footprint in Singapore, and adds capabilities in anatomic pathology and nutritional chemistry. The Singapore facility continues to provide services that include chemistry, immunology, hematology, flow cytometry, genomics, anatomic pathology, and microbiology. 
 
“For the last 13 years Covance has provided central laboratory testing services in Singapore, where we have seen increasing demand for efficient, high-quality clinical trial data and support,” said Jon Koch, corporate vice president and global general manager, Central Laboratory Services, Covance. “This expansion will help us better serve both our local and multinational customers’ R&D needs in key therapeutic areas like oncology and metabolic diseases while reflecting Covance’s continued commitment to the Asia Pacific region.”